Please assess the completion status of the following clinical trial:

Trial Title: Faslodex in McCune-Albright Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females less than or equal to 10 years of age (prior to 11th birthday)~* Diagnosis of MAS~* PPP associated with MAS~Exclusion Criteria:~* Received any prior treatment for PPP associated with MAS with fulvestrant~* Abnormal platelet count or liver function tests~* Bleeding disorders~* Long term anticoagulation therapy~* Known hypersensitivity to any component of the study drug

- Gender: FEMALE
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Fulvestrant (Type: EXPERIMENTAL): Participants will receive intramuscular injection of fulvestrant 2 mg/kg or 4 mg/kg (First 10 participants will be dosed at 2 mg/kg then increased to 4 mg/kg. All subsequent participants will be dosed at 4 mg/kg) into the buttock or thigh monthly for 12 months or until the participant demonstrates lack of efficacy based upon one or more of the primary endpoints or experiences a serious drug-related toxicity requiring treatment discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).